FDA Adverse Event Injury Summary report: N

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 1884708 · Received October 25, 2010

Report

Report Number
2024168-2010-02246
Event Type
Injury
Date Received
October 25, 2010
Date of Event
June 9, 2010
Report Date
September 30, 2010
Manufacturer
ABBOTT VASCULAR-CARDIAC THERAPIES
Product Code
NIQ
PMA / PMN Number
P070015
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THERE WAS NO REPORTED PRODUCT DEFICIENCY. THE REPORTED PT EFFECTS OF ANGINA AND RESTENOSIS, AS LISTED IN THE PRODUCT INSTRUCTIONS FOR USE, ARE KNOWN ADVERSE EVENT ASSOCIATED WITH CORONARY STENTING PROCEDURES. ALTHOUGH CONCLUSIVE CAUSE FOR THE REPORTED PT EFFECTS AND THE RELATIONSHIP TO THE DEVICE, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURE, DESIGN OR LABELING.

Description of Event or Problem · 1

IT WAS REPORTED THAT ON (B)(6) 2006, THE PT UNDERWENT STENTING IN THE PREDILATED MID LEFT ANTERIOR DESCENDING ARTERY (LAD) WITH ONE XIENCE V STENT. ON (B)(6) 2006, THE PT EXPERIENCED STABLE ANGINA, BUT THERE WAS NO TREATMENT PROVIDED. ON (B)(6) 2010, THE PT EXPERIENCED STABLE ANGINA PECTORIS REQUIRING TREATMENT WITH THREE XIENCE STENTS IN THE PROXIMAL, MID, AND DISTAL LAD WHERE THE STENOSIS WAS FOUND TO BE WITHIN 5 MM OF THE INDEX XIENCE STENT. THE PT WAS DISCHARGED FROM THE HOSPITAL ON (B)(6) 2010. THERE WAS NO ADVERSE PT SEQUELA. THERE WAS NO ADDITIONAL INFO PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM NIQ ABBOTT VASCULAR-CARDIAC THERAPIES NA 60608P1

Patients

Seq Age Sex Outcome Treatment
1 76 YR Hospitalization| R DIL CATH: HINODE